RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of $78.00. The company’s shares opened today at $47.95.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for Rhythm Pharmaceuticals in a research report ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals RYTM during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Given this risk, we thought we'd take a look at whether Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...